Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
1 hedge funds and large institutions have $425K invested in Revance Therapeutics, Inc. in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 170 closing their positions.
99% less funds holding
Funds holding: 173 → 1 (-172)
100% less capital invested
Capital invested by funds: $249M → $425K (-$249M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 170
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$26.1M |
| 2 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$18M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.1M |
| 4 |
OBAM
ODDO BHF Asset Management
Paris,
France
|
-$15.5M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
-$12.8M |
RVNC Hedge Fund Activity: Q1 2025 in Review
1 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2025, worth a combined $425K — down 100% from $249M a quarter earlier.
Sellers outnumbered buyers: 170 funds closed out of RVNC and 0 opened new positions — a net loss of 170 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $26.1M sold.
- 1 institutional investor held Revance Therapeutics, Inc. (RVNC) as of Q1 2025, down from 173 in Q4 2024.
- Funds reported $425K of Revance Therapeutics, Inc. stock for Q1 2025, down 100% quarter-over-quarter.
- 0 funds opened new Revance Therapeutics, Inc. positions in Q1 2025 and 170 closed out, a net change of -170 holders.
- The largest Revance Therapeutics, Inc. seller in Q1 2025 was BlackRock, an estimated $26.1M sold.
Based on aggregated 13F filings for Q1 2025.